Curanex Pharmaceuticals reported total assets of $5.07M and total liabilities of $0.29M for the quarter ended Jun 2026, up 879.6% year over year. This balance sheet covers 6 quarters of results from Sep 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Sep2024 | Dec2024 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Current Assets | ||||||
| Cash & EquivalentsCash & Equiv. | 0.24M | 0.15M | 0.11M | 5.83M | 4.97M | 2.94M |
| Cash & Current Investments | 0.24M | 0.15M | 0.11M | 5.83M | 4.97M | 2.94M |
| Prepaid Assets | 0.37M | 0.60M | 8.59M | 6.25M | 1.85M | |
| Current Assets | 0.52M | 0.71M | 14.42M | 11.23M | 4.79M | |
| Non-Current Assets | ||||||
| Long-Term Deferred Tax | 0.13M | 0.17M | 0.24M | 1.02M | ||
| Non-Current Assets | 0.08M | 0.06M | 0.35M | 0.28M | ||
| Assets | 0.52M | 0.79M | 14.48M | 11.58M | 5.07M | |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payables | 0.01M | 269.00 | 0.11M | 0.00M | 154.00 | |
| Payables | 0.01M | 269.00 | 0.11M | 0.00M | 154.00 | |
| Accumulated Expenses | 0.01M | 0.00M | 0.01M | 0.01M | 0.01M | |
| Current Leases | 0.07M | 0.06M | 0.12M | 0.09M | ||
| Current Taxes | 25.00 | 25.00 | ||||
| Total Current Liabilities | 0.01M | 0.08M | 0.19M | 0.14M | 0.10M | |
| Non-Current Liabilities | ||||||
| Non-Current Debt | 0.40M | |||||
| Operating Leases | 0.08M | 0.06M | 0.35M | 0.28M | ||
| Total Liabilities | -0.62M | 0.01M | 0.48M | 0.19M | 0.36M | 0.29M |
| Shareholder's Equity | ||||||
| Total Debt | 0.40M | |||||
| Common Equity | 0.62M | 0.50M | 0.31M | 14.29M | 11.22M | 4.79M |
| Liabilities and Shareholders Equity | 0.52M | 0.79M | 14.48M | 11.58M | 5.07M | |
| Retained Earnings | -0.62M | -0.82M | -1.77M | -4.85M | -11.29M | |
| Preferred Shares | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |